# 1 Seroprevalence, correlates and kinetics of SARS-CoV-2 Nucleocapsid

# 2 IgG antibody in healthcare workers at a tertiary hospital: A prevaccine

## 3 census study

Daniel Maina<sup>1\*</sup>, Geoffrey Omuse<sup>1</sup>, George Ong'ete<sup>2</sup>, Patrick Mugaine<sup>1</sup>, Shahin Sayed<sup>1</sup>, Zahir Moloo<sup>1,3</sup>, Reena Shah<sup>4</sup>, Anthony Etyang<sup>5</sup>, Rodney Adam<sup>1,4</sup>

<sup>1</sup>Department of Pathology & Laboratory Medicine, Aga Khan University Hospital, Nairobi

- <sup>2</sup> Occupational Safety & Health, Aga Khan University Hospital, Nairobi
- <sup>3</sup> Aga khan Health Services

<sup>4</sup> Department of Internal Medicine, Aga Khan University Hospital Nairobi

<sup>5</sup> KEMRI–Wellcome Trust Research Programme, Kilifi, Kenya

\*Corresponding author Email: <u>daniel.maina@aku.edu</u>

4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

## 26 Abstract

20 27	<b>Background:</b> Healthcare workers are perceived to be a high-risk group for acquiring SAR-CoV-2
28	infection, and more so in countries where COVID-19 vaccination uptake is low. Serosurveillance
29	may best determine the true extent of SARS-CoV-2 infection since most infected HCWs may be
30	asymptomatic or present with only mild symptoms. Over time, determining the true extent of
31	SARS-CoV-2 infection could inform hospital management and staff whether the preventive
32	measures instituted are effective and valuable in developing targeted solutions.
33	Methods: This was a census survey study conducted at the Aga Khan University Hospital,
34	Nairobi, between November 2020 and February 2021 before the implementation of the COVID-
35	19 vaccination. The SARS-CoV-2 nucleocapsid IgG test was performed using a chemiluminescent
36	assay.
37	Results: One thousand six hundred thirty-one (1631) staff enrolled, totalling 60% of the
37 38	<b>Results:</b> One thousand six hundred thirty-one (1631) staff enrolled, totalling 60% of the workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay
38	workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay
38 39	workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay sensitivity of 86%) was 21.4% (95% CI; 19.2-23.7). The HCW groups with higher prevalence
38 39 40	workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay sensitivity of 86%) was 21.4% (95% CI; 19.2-23.7). The HCW groups with higher prevalence included pharmacy (25.6%), outreach (24%), hospital- based nursing (22.2%) and catering staff
38 39 40 41	workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay sensitivity of 86%) was 21.4% (95% CI; 19.2-23.7). The HCW groups with higher prevalence included pharmacy (25.6%), outreach (24%), hospital- based nursing (22.2%) and catering staff (22.6%). Independent predictors of a positive IgG result included prior COVID-19 like symptoms,
38 39 40 41 42	workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay sensitivity of 86%) was 21.4% (95% CI; 19.2-23.7). The HCW groups with higher prevalence included pharmacy (25.6%), outreach (24%), hospital- based nursing (22.2%) and catering staff (22.6%). Independent predictors of a positive IgG result included prior COVID-19 like symptoms, odds ratio (OR) 1.9 [95% confidence interval (CI) 1.3-2.9, p=0.002], and a prior positive SARS-
<ol> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> </ol>	workforce. The overall crude seroprevalence was 18.4% and the adjusted value (for assay sensitivity of 86%) was 21.4% (95% CI; 19.2-23.7). The HCW groups with higher prevalence included pharmacy (25.6%), outreach (24%), hospital- based nursing (22.2%) and catering staff (22.6%). Independent predictors of a positive IgG result included prior COVID-19 like symptoms, odds ratio (OR) 1.9 [95% confidence interval (CI) 1.3-2.9, p=0.002], and a prior positive SARS-CoV-2 PCR result OR 11.0 (CI: 7.2-18.0, p<0.001). Age, sex, comorbidities or working in a COVID-

- **Conclusions:** The prevalence of anti- SARS-CoV-2 nucleocapsid IgG among HCWs was lower
- 48 than in the general population. Staff working in clinical areas were not at increased risk when
- 49 compared to staff working in non-clinical areas.

#### Introduction

	introduction
60 61	SARS-CoV-2 infection remains a threat to public health, especially in low resource
62	settings where vaccine coverage remains low. As of 2 <sup>nd</sup> March 2022, only 13.9% of the Kenyan
63	population was fully vaccinated (1). The positivity rate with PCR testing in the general
64	population continues to fluctuate and was less than 1% at the start of March 2022. Admissions
65	to hospitals reflect this fluctuation. Data on the infection rates of healthcare staff in Kenya are
66	scanty and often do not include details of exposure risk.
67	The country had 7,466 infected healthcare workers (HCWs) reported as of September
68	2021. Etyang et al. reported seroprevalences of 43.8% (urban), 12.6% (rural) and 11.5% (rural)
69	in three counties in Kenya (2). The challenges facing HCW on the continent include inadequate
70	personal protective equipment (PPE) and limited SARS-CoV-2 testing of populations that seek
71	medical care, which leaves workers vulnerable (3), as was especially true before the provision
72	of SARS-CoV-2 vaccination to HCW.
73	Although infections in HCWs are often attributed to occupational exposure, that is not
74	always the case. At Aga Khan University Hospital Nairobi (AKUHN), personal protective
75	equipment (PPE) appropriate for the level of clinical care has been routinely provided since the
76	beginning of the Kenyan outbreak. In addition, routine tests of admitted patients were
77	implemented. Therefore, we wished to know the level of risk to HCWs where PPE and testing
78	are readily available.
79	Although liberal PCR testing of HCWs has been done at AKUHN throughout the
80	outbreak, asymptomatic HCWs were not routinely tested. Since asymptomatic infections have
81	comprised a significant percentage of infections in some series, it is possible that a significant

82	number of staff infections have been missed (4). The serosurvey helped address the suitability
83	of our approaches to staff safety.
84	
85	Materials and Methods
86	This research was a census study in which all HCW at AKUHN were eligible to
87	participate. The staff were sensitised about the study through posters, institutional email
88	addresses and group talks. One thousand, six hundred thirty-one staff consented and were
89	recruited in the study (>60% of the workforce). The study lasted from November 2020 to
90	February 2021, before the implementation of COVID-19 vaccination in the hospital.
91	Staff were categorised into five groups based on the perceived risk of COVID-19
92	exposure at the workplace:
93	Clinical COVID-19 areas: COVID-19 isolation wards, Intensive Care Unit (ICU), High
94	Dependence Unit (HDU), Accident and Emergency (A&E) triage
95	Non-COVID-19 clinical areas: general wards, outpatient clinics
96	Allied health: laboratory, radiology, pharmacy
97	Support staff: catering, facilities, housekeeping
98	<ul> <li>Academic/Administration areas</li> </ul>
99 100	Specimen collection & assay
101	A phlebotomist collected 5-10 ml of blood in a serum separator vacutainer (Greiner Bio-
102	One GmbH – Germany) from each participant. In all cases, blood samples were labelled with a
103	unique study identifier, centrifuged and serum separated within 24 hours of collection.

## 105 Laboratory testing

106	The antibody test was performed using a chemiluminescent assay (Abbott, USA),
107	according to the manufacturer's instructions and standard operating procedures. The Abbott
108	qualitative anti-nucleocapsid CoV-2 IgG assay for SARS has a manufacturer's stated sensitivity of
109	100% 14 days after the onset of symptoms and a specificity of 99.6%. Our laboratory evaluation
110	using 54 samples from known COVID-19 patients showed a sensitivity of 86%, 14 days after the
111	onset of symptoms, and a specificity of 100% using 20 samples before COVID-19 (unpublished
112	data). An independent evaluation of this kit by Public Health England reported a sensitivity of
113	93.9% for samples $\geq$ 14 days post-symptom onset of symptoms and a specificity of 100% (5).
114	The default result unit for the SARS-CoV-2 IgG assay is Index (S/C), with a cutoff of 1.40.
115	This study was conducted according to the criteria set by the declaration of Helsinki on Human
116	research. The protocol was approved by the Ethics Review Committee of Aga Khan University
117	Nairobi (Ref: 2020/IERC-129 v4).
118	Written informed consent was obtained from all participants.
119	
120	Data collection and Analysis
121	Stata 16 (StataCorp, Texas, USA) was used to perform the statistical analysis.
122	The demographic and risk details of the patients were captured by filling in a guided
123	questionnaire. Descriptive statistics are presented as medians [interquartile range (IQR)] or
124	means (standard deviation, SD) and percentages (proportions), where appropriate. Crude
125	seroprevalence figures were adjusted for the performance (sensitivity 86%, specificity 100%) of
126	the nucleocapsid assay in our evaluation (6),.

127	Risks (associations) were analysed using logistic regression analyses and chi-square
128	statistics, presented here, respectively, as odds ratio (OR) with 95% confidence interval (95% CI)
129	and chi statistics with p-value.
130	Antibody kinetics were evaluated for participants with documented SARS-CoV-2 PCR
131	results and compared with the proportions of HCWs with positive IgG at different time points
132	between the PCR and antibody tests.
133	
134	Results
135	One thousand six hundred thirty-one (1,631) staff members, both AKUHN and
136	contracted employees, participated in the study. This figure represented 60% of the hospital
137	workforce. The median age was 35 years (interquartile range 30-45). AKUHN employees
138	comprised 86.7% of the study participants. Males made up 44% of the tested staff, and the
139	overall crude seroprevalence of SARS-CoV-2 in the study was 18.4%, adjusted to 21.4% (95% CI;
140	19.2-23.7).
141	The seroprevalence among AKUHN staff (22.0%) was not significantly different from that
142	of contracted workers (17.7%) (p-value = 0.193). The proportion of staff with SARS-CoV-2
143	antibodies varied between the different cadres within these two broad groups. Notable cadres
144	with higher proportions of exposed personnel included pharmacy (25.6%), outreach (24%),
145	nursing (22.2%) and catering (22.6%), as shown in Table 1.
146	
147	
148 149	
- 15	

# 150 Table 1: SARS-CoV-2 anti- nucleocapsid IgG antibody prevalence in HCWs

	Total	Seropositive	Adjusted Prevalence
		n (crude prevalence)	(95% confidence
			interval)
All	1631	300 (18.4%)	21.4 (19.2-23.7)
Males	716	126 (17.6%)	20.5 (17.4-24.0)
Females	915	174 (19.0%)	22.1 (19.3-25.2)
Age			
20-29	368	72 (19.6%)	22.8% (18.4-27.8)
30-39	666	124 (18.6%)	21.6% (18.4-26.2)
40-49	392	72 (18.4%)	21.4% (17.2-25.0)
50-59	145	27 (18.6%)	21.6% (15.2-30.0)
≥60	45	3 (6.7%)	7.8% (2.5-21.8)
Symptomatic			
(preceding 3			
months)			
Yes	750	189 (25.2%)	29.3% (26.1-32.7)
No	881	111 (12.6%)	14.7% (12.4-17.2)
AKU Staff	1414	267 (18.9%)	22.0% (19.8-24.4)
<b>Contracted Staff</b>	217	33 (15.2%)	17.7% (12.8-24.0)
<b>AKUHN Divisions</b>			
Nursing	347	77 (22.2%)	25.8 (21.0-31.3)
Pharmacy	43	11 (25.6%)	29.8 (14.8-40.6)
Outreach	117	28 (24.0%)	27.9 (19.9-37.8)
Pathology	84	14 (16.7%)	19.4 (11.7-30.5)
Diagnostic imaging	53	9 (17.0%)	19.8 (10.6-34.3)
Medical services	466	78 (16.7%)	19.4 (15.7-23.7)
Others (nonclinical)	304	57 (18.8%)	21.9 (16.9-27.4)
Risk Based			
Clinical Covid	209	49 (23.4%)	27.2 (21.2-34.5)
Non-Covid Clinical	530	99 (18.7%)	21.7 (18.1-25.9)
Allied health	234	37 (15.8%)	18.4 (13.6-24.5)
Support	185	35 (18.9&)	22.0 (16.2-29.3)
Admin/Academic	249	46 (18.5%)	21.5 (16.4-27.7)
Contracted staff			
Catering	53	12 (22.6%)	26.3 (14.3-42.1)
Housekeeping	103	14 (13.6%)	15.8 (8.8-25.3)
Security	35	4 (11.4%)	13.3 (3.7-31.0)

	Others	26	3 (11.5%)	13.4 (2.9-35.1)
152 153 154 155	<b>Key:</b> Clinical Covid: isolation Allied health: laboratory, rad Academic/Administration: no	iology, pharmacy; Support st	aff: catering, facilities, house	-
156	Seven hundred s	ixty-nine HCW (47%) ha	d taken a SARS-CoV-2 P(	CR test prior to the
157	study, with 136 (18%) co	onfirmed positive. Serop	revalence was 66.2% an	nong HCWs with a
158	positive PCR test and 13	.5 % among those with a	a negative result (p<0.00	01). Slightly less than
159	half (46%) of the 1631 H	CW reported symptoms	consistent with COVID-	19 in the previous 3
160	months prior to the stud	dy. The most prevalent s	ymptoms were headach	e (52%), sneezing
161	(51%), cough (42%) and	fever (16%). Adjusted se	eroprevalence among sy	mptomatic and
162	asymptomatic HCWs wa	is 29.3% and 14.7%, resp	pectively (p<0.001).	
163				
164	Predictors of a positive	anti-SARS-CoV-2 nucleo	ocapsid IgG test	
164 165			ocapsid IgG test PCR) irrespective of test	result increased the
		y tested for COVID-19 (F	PCR) irrespective of test	
165	Having previous	y tested for COVID-19 (F with the antibody test, (	PCR) irrespective of test DR 1.7 (95% CI: 1.3-2.2, j	o <0.001) (Table 2). The
165 166	Having previousl odds of testing positive	y tested for COVID-19 (F with the antibody test, ( n those who had tested	PCR) irrespective of test DR 1.7 (95% CI: 1.3-2.2, positive with PCR (OR 1	o <0.001) (Table 2). The 2.5 95% CI: 8.2-19.1,
165 166 167	Having previousl odds of testing positive odds were even higher i	y tested for COVID-19 (F with the antibody test, ( n those who had tested ed to those who had ex	PCR) irrespective of test DR 1.7 (95% CI: 1.3-2.2, positive with PCR (OR 1 perienced flu-like sympt	o <0.001) (Table 2). The 2.5 95% CI: 8.2-19.1, oms in the previous 3
165 166 167 168	Having previousl odds of testing positive odds were even higher i p<0.001). This also appli	y tested for COVID-19 (F with the antibody test, G n those who had tested ed to those who had ex ent in the study, OR 2.3	PCR) irrespective of test DR 1.7 (95% CI: 1.3-2.2, positive with PCR (OR 1 perienced flu-like sympt (95% CI 1.8-3.0, p<0.002	o <0.001) (Table 2). The 2.5 95% CI: 8.2-19.1, oms in the previous 3 1); antibody test
165 166 167 168 169	Having previousl odds of testing positive odds were even higher i p<0.001). This also appli months prior to enrollm	y tested for COVID-19 (F with the antibody test, G n those who had tested ed to those who had ex ent in the study, OR 2.3 ter the PCR test, OR 1.6	PCR) irrespective of test DR 1.7 (95% CI: 1.3-2.2, positive with PCR (OR 1 perienced flu-like sympt (95% CI 1.8-3.0, p<0.002 (95% CI 1.02-2.54, p =0.	o <0.001) (Table 2). The 2.5 95% CI: 8.2-19.1, oms in the previous 3 1); antibody test
165 166 167 168 169 170	Having previousl odds of testing positive odds were even higher i p<0.001). This also appli months prior to enrollm performed 2-4 weeks af	y tested for COVID-19 (F with the antibody test, G n those who had tested ed to those who had ex ent in the study, OR 2.3 ter the PCR test, OR 1.6 patients, OR 1.5 (95% CI	PCR) irrespective of test DR 1.7 (95% CI: 1.3-2.2, positive with PCR (OR 1 perienced flu-like sympt (95% CI 1.8-3.0, p<0.002) (95% CI 1.02-2.54, p =0.	o <0.001) (Table 2). The 2.5 95% CI: 8.2-19.1, oms in the previous 3 1); antibody test 041); or reported daily

- 174 multivariate analysis revealed an independent association with only cough, fever and loss of
- 175 smell.
- 176
- 177 Table 2: Risk factors for a positive anti-nucleocapsid IgG result

	SARS-CoV-2 IgG Positive n (%)	Odds Ratio (95% Cl)	p-value
Previously tested for SARS-CoV-2 (PCR)			
Yes	175 (22.8)	1.7 (1.3-2.2)	<0.001
No	124 (14.5)		
Time interval between PCR and			
serology test			
<2 weeks	25 (23.6)	1.1 (0.6-1.7)	0.855
2-4 weeks	32 (30.8)	1.6 (1.02-2.54)	0.041
1-2 months	37 (25.7)	1.2 (0.8-1.8)	0.375
>2 months	80 (19.7)	0.7 (0.48-0.95)	0.025
COVID-19 PCR			
result			0.001
Positive	90 (66.2)	12.5 (8.2-19.1)	<0.001
Negative	85 (13.5)		
Flu-like symptoms past 3 months			
Yes	189 (25.2)	2.3 (1.8-3.0)	<0.001
No	111 (12.6)	, , ,	
Univariate analysis			
of individual			
symptoms			
Cough	93 (29.6)	2.3 (1.7-3.0)	<0.001
Sneezing	92 (24.2)	1.6 (1.2-2.1)	0.001
Fever	50 (42.4)	3.7 (2.5-5.5)	<0.001
Running nose	87 (24)	1.6 (1.2-2.1)	0.002
Chest pain	29 (26.6)	1.7 (1.1-2.6)	0.023
Headache	102 (26)	1.8 (1.4-2.4)	< 0.001
Loss of smell	59 (67.8)	11.4 (7.1-18.2)	<0.001
Multivariate		Adjusted OR	
analysis symptoms		Aujusieu UN	
analysis symptoms			

Cough Fever Loss of smell		1.7 (1.2-2.4) 1.7 (1.1-2.8) 8.6 (5.2-14.3)	0.004 0.026 <0.001
Household contacts or workmates diagnosed with covid Yes No	163 (19.6) 137 (17.2)	1.2 (0.9-1.5)	0.220
Work involves frequent (daily) close contact with COVID-19 patients Yes No	190 (21.1) 110 (15.1)	1.5 (1.2-2.0)	0.002
Hospital Location Risk (clinical COVID) Yes No	49 (22) 251 (18)	1.3 (0.9-1.8)	0.171

178

179 Age, sex, and comorbidities (diabetes and hypertension) were not risk factors for a

180 positive SARS-CoV-2 lgG test .

181 A binomial logistic regression was run to understand the effects of a positive COVID-19

182 PCR result, flu-like symptoms 3 months prior to testing, working in close contact with COVID-19

patients and antibody test performed 2-4 weeks after PCR test on the likelihood of being

184 seropositive. A positive PCR result and flu-like symptoms predicted seropositivity. However,

interacting daily with COVID-19 patients and the time interval between PCR and antibody tests

186 did not achieve statistical significance (Table3).

187

188

## 190 Table 3: Predictors of a positive anti-nucleocapsid IgG result

		Univariate		Multivariate Mode	ela
		Odds Ratio (95% CI)	p-value	Odds Ratio (95% CI)	p-value
	SARS-CoV-2 PCR result +	12.5 (8.2-19.1)	<0.001	11.0 (7.2-17.0)	<0.001
	Flu-like symptoms past 3 months	2.32 (1.8-3.0)	<0.001	1.9 (1.3-2.9)	0.002
	Work involves frequent (daily) close contact with COVID-19 patients	1.5 (1.2-2.0)	0.002	1.3 (0.8-1.8)	0.267
	Time interval (2-4 weeks) Between PCR and antibody test	1.6 (1.02-2.54)	0.041	1.2 (0.7-2.1)	0.450
					R FOULT
3 1	<sup>a</sup> Model includes risk factors wi presence of flu-like symptoms, between the PCR and antibody	frequent close conta	• •		
8 1 5	presence of flu-like symptoms,	frequent close conta	• •		
3 1 5	presence of flu-like symptoms, between the PCR and antibody	frequent close conta test	ct with COVID	-19 patients at the wo	orkplace and ti
3 1 5 7	presence of flu-like symptoms, between the PCR and antibody COVID-19 IgG dynamics	frequent close conta test	ct with COVID	-19 patients at the wo	orkplace and ti
3 1 5 7 8	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i	frequent close conta test n participants who test and sharply de	ct with COVID tested positiv clined therea	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The	orkplace and ti by PCR peaked odds of testin
3 1 5 7 3	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR	frequent close conta test n participants who test and sharply de est if performed mo	ct with COVID tested positiv clined therea re than 2 mo	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR (	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-
3 1 5 7 3 9	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR antibody positive were lowe	frequent close conta test n participants who test and sharply de est if performed mo	ct with COVID tested positiv clined therea re than 2 mo	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR (	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-
3 4 5 7 3 9 1	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR antibody positive were lowe 0.95). The PCR negative grou	frequent close conta test n participants who test and sharply de est if performed mo up had a steady but	ct with COVID tested positiv clined therea re than 2 mo slow decline	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR C in seroprevalence t	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-
3 4 5 7 3 9 0 1	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR antibody positive were lowe 0.95). The PCR negative grou same period.	frequent close conta test n participants who test and sharply de est if performed mo up had a steady but	ct with COVID tested positiv clined therea re than 2 mo slow decline	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR C in seroprevalence t	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-
2 3 4 5 7 8 9 0 1 2 3 4	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR antibody positive were lower 0.95). The PCR negative grou same period. <b>Fig 1. Proportion of HCWs with</b> <b>Fig 2. Antibody index at variou</b>	frequent close conta y test in participants who test and sharply de est if performed mo up had a steady but h positive antibody o us time points post-SA	ct with COVID tested positiv clined therea re than 2 mo slow decline <b>ver time after</b> <b>ARS-CoV-2-19</b>	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR C in seroprevalence t PCR test PCR+ test	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-
3 4 5 7 3 9 0 1 2 3 4 5	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR antibody positive were lowe 0.95). The PCR negative grou same period. <b>Fig 1. Proportion of HCWs with</b>	frequent close conta y test in participants who test and sharply de est if performed mo up had a steady but h positive antibody o us time points post-SA	ct with COVID tested positiv clined therea re than 2 mo slow decline <b>ver time after</b> <b>ARS-CoV-2-19</b>	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR C in seroprevalence t PCR test PCR+ test	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-
3 4 5 7 8 9 0 1 2 3	presence of flu-like symptoms, between the PCR and antibody <i>COVID-19 IgG dynamics</i> The seroprevalence i 2 months following the PCR antibody positive were lower 0.95). The PCR negative grou same period. <b>Fig 1. Proportion of HCWs with</b> <b>Fig 2. Antibody index at variou</b>	frequent close conta y test in participants who test and sharply de est if performed mo up had a steady but h positive antibody o us time points post-SA	ct with COVID tested positiv clined therea re than 2 mo slow decline <b>ver time after</b> <b>ARS-CoV-2-19</b>	-19 patients at the wo ve for SARS-CoV-2 b fter (Figs 1&2). The nths after PCR, OR C in seroprevalence t PCR test PCR+ test	orkplace and ti by PCR peaked odds of testin 0.7 (CI 0.48-

208	We determined the seroprevalence and kinetics of SARS-CoV2 nucleocapsid IgG
209	antibodies in HCW prior to the advent of the COVID-19 vaccine when little information was
210	available on the clinical implications (immunity) of seroconverting. This was also before any
211	variant of concern had been reported in the country. The adjusted seroprevalence of 21% was
212	well below any reported in a public urban hospital (43.8%) in Nairobi (2). Whether the strict
213	COVID-19 prevention measures enforced early in AKUHN contributed substantially to the
214	relatively lower seroprevalence has not been determined. Hospitals in rural areas had lower
215	rates reflecting low community transmission (2). Early in the COVID-19 pandemic, Nairobi was
216	the epicentre of the infection, which later spread to other parts of the country.
217	Elsewhere on the continent, seroprevalence among HCW ranged from 0% to 45.1%,
218	with the highest prevalence in Nigeria (7).
219	Contrary to previous assumptions, there was no significant difference in seroprevalence
219 220	Contrary to previous assumptions, there was no significant difference in seroprevalence between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas
220	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas
220 221	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the
220 221 222	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the community. During the same period, a study conducted in India reported similar figures
220 221 222 223	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the community. During the same period, a study conducted in India reported similar figures between HCWs and the general public (25.6% versus 23.2%) (8). Here in Kenya, a study
220 221 222 223 224	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the community. During the same period, a study conducted in India reported similar figures between HCWs and the general public (25.6% versus 23.2%) (8). Here in Kenya, a study reported a higher prevalence (61.8%) among blood donors than the prevailing seroprevalence
220 221 222 223 224 225	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the community. During the same period, a study conducted in India reported similar figures between HCWs and the general public (25.6% versus 23.2%) (8). Here in Kenya, a study reported a higher prevalence (61.8%) among blood donors than the prevailing seroprevalence among HCWs in Nairobi for the period January through March 2021(9), reflecting the high
220 221 222 223 224 225 226	between frontline staff (high-risk work-based exposure) and staff working in nonclinical areas (low-risk work exposure), suggesting that most of the SARS-CoV-2 infections occurred in the community. During the same period, a study conducted in India reported similar figures between HCWs and the general public (25.6% versus 23.2%) (8). Here in Kenya, a study reported a higher prevalence (61.8%) among blood donors than the prevailing seroprevalence among HCWs in Nairobi for the period January through March 2021(9), reflecting the high community transmission prevalent during the study period.

prevalence, possibly explained by confined working spaces with close contact between the staffin the two areas.

Testing positive for SARS-CoV-2 by PCR and having flu-like symptoms independently predicted a positive SARS-CoV-2 antibody result. The three symptoms that independently predicted a positive antibody result were loss of smell, followed by fever and cough (adjusted OR 8.7, 1.7, 1.7, respectively). Other studies have reported similar symptoms among HCWs elsewhere (12, 13).

237 Symptomatic staff had mild COVID-19 disease, none of which required hospitalisation. 238 The hospital workforce is relatively young (mean age of 37 years) and has few comorbidities, 239 which could partly explain the mild COVID-19 disease seen in the facility.

240 Correct interpretation of serology test results requires a proper understanding of the antibody dynamics, as demonstrated in our findings. Testing for nucleocapsid IgG antibodies 241 242 three months after SARS-CoV-2 infection is likely to miss a significant proportion of exposed people. Only 20% of HCW with confirmed infection in our study were positive for IgG antibodies 243 244 at three months and beyond. Van Elslande et al. reported that anti-nucleocapsid IgG antibody levels of SARS-CoV-2 steadily decreased after 2 months up to 8 months after PCR, while another 245 246 study showed a decline in positivity starting at 6 months onward after the onset of COVID-19 247 symptoms or testing (14, 15).

All participants in our study had mild disease or were asymptomatic and the kinetics described here may not apply to those with severe COVID-19 disease, which has been associated with earlier and higher antibody levels compared with asymptomatic infections (16, 17).

#### 252

#### 253 Conclusions

- 254 The prevalence of anti- SARS-CoV-2 nucleocapsid IgG among HCWs was high but lower
- than in the general population. There were no statistically significant differences in
- 256 seroprevalence between the clinical areas and the rest of the hospital. Independent predictors
- of a seropositive result were a positive SARS-CoV-2 PCR result and flu-like symptoms in the 3
- 258 months prior to joining the study. Seropositivity peaked 2 months after a positive PCR test and
- then declined.
- 260

#### 261 Acknowledgements:

- 262 Much appreciation to the administration of AKUHN for facilitating the study. Thanks to Cyrus Matheka,
- 263 David Kawalya and Assumpta Chege for the logistical assistance.
- 264

#### 265 **References:**

- 266
- Coronavirus (COVID-19) Vaccinations 2022 [Available from: <u>https://ourworldindata.org/covid-vaccinations</u>.
- Etyang AO, Lucinde R, Karanja H, Kalu C, Mugo D, Nyagwange J, et al. Seroprevalence of Antibodies
   to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. Clinical
   Infectious Diseases. 2021.
- 272 3. WHO. COVID-19 WHO African Region: External situation report 12. 2020.
- Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare
   workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. Elife.
   2020;9:e58728.
- England PH. Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARSCoV-2 antibodies.; June 2020.
- Sempos CT, Tian L. Adjusting coronavirus prevalence estimates for laboratory test kit error.
   American journal of epidemiology. 2021;190(1):109-15.

Nüller SA, Wood RR, Hanefeld J, El-Bcheraoui C. Seroprevalence and Risk Factors of COVID-19 in
 Healthcare Workers From Eleven African Countries: A Scoping Review and Appraisal of Existing
 Evidence. Health policy and planning. 2021.

- Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. SARS CoV-2 seroprevalence among the general population and healthcare workers in India, December
   2020–January 2021. International Journal of Infectious Diseases. 2021;108:145-55.
- Uyoga S, Adetifa IM, Otiende M, Yegon C, Agweyu A, Warimwe GM, et al. Prevalence of SARS-CoV-2
   antibodies from a national serosurveillance of Kenyan blood donors, January-March 2021. JAMA.
   2021;326(14):1436-8.
- 10. Mostafa A, Kandil S, El-Sayed MH, Girgis S, Hafez H, Yosef M, et al. SARS-CoV-2 seroconversion
   among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective
   cohort study. International Journal of Infectious Diseases. 2021;104:534-42.
- Prakash O, Solanki B, Sheth J, Makwana G, Kadam M, Vyas S, et al. SARS-CoV2 IgG antibody:
   Seroprevalence among health care workers. Clinical epidemiology and global health.
   2021;11:100766.
- Magnavita N, Tripepi G, Di Prinzio RR. Symptoms in health care workers during the COVID-19
   epidemic. A cross-sectional survey. International journal of environmental research and public
   health. 2020;17(14):5218.
- 298 13. Gholami M, Fawad I, Shadan S, Rowaiee R, Ghanem H, Khamis AH, et al. COVID-19 and healthcare
  299 workers: A systematic review and meta-analysis. International Journal of Infectious Diseases.
  300 2021;104:335-46.
- 14. Van Elslande J, Oyaert M, Ailliet S, Van Ranst M, Lorent N, Weygaerde YV et al. Longitudinal follow up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after
   infection. Journal of Clinical Virology. 2021;136:104765.
- Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Wanlapakorn N, Sudhinaraset N, et al. Long-term
   specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients. Scientific
   reports. 2021;11(1):1-8.
- 307 16. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of
   308 novel coronavirus disease 2019. Clinical Infectious Diseases. 2020.
- 17. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J et al. Different longitudinal patterns of nucleic acid
   and serology testing results based on disease severity of COVID-19 patients. Emerging microbes &
   infections. 2020;9(1):833-6.

# Anti-SARS-CoV2 nucleocapsid IgG dynamics




Fig 1




Fig 2